OBJECTIVE: To probe into the treatment effects of nimodipine combined with high frequency repetitive transcranial magnetic stimulation（ r TMS） in the treatment of patients with subcortical non-dementia vascular cognitive impairment. METHODS: Totally 116 patients with subcortical non-dementia vascular cognitive impairment admitted into the Third Hospital of Changsha from Jun. 2018 to Jun. 2019 were extracted to be divided into the r TMS treatment group and the combination treatment group via the random number table

with 58 cases in each group. The r TMS treatment group was treated with r TMS

while the combination treatment group received nimodipine on the basis of r TMS. Montreal cognitive assessment（ MoCA） score

Barthel score

Hamilton anxiety scale（ HAMA） and Hamilton depression scale（ HAMD） score of two groups were observed. The serum S100β protein

neuron specific enolase（ NSE）

insulin-like growth factor 1（ IGF-1）

tumor necrosis factor α（ TNF-α）

interleukin-1β（ IL-1β）

interleukin-6（ IL-6）

glutathione peroxidase（ GSH-Px）

lipid peroxide（ LPO） and malondialdehyde（ MDA） of two groups were compared. The clinical efficacy of two groups was analyzed. RESULTS: After treatment

MoCA score and Barthel score of patients in the combination treatment group were significantly higher than those in the r TMS treatment group; the serum levels of S100β protein and NSE in the combination treatment group were significantly lower than those in the r TMS treatment group

and the level of IGF-1 was significantly higher than that in the r TMS treatment group

with statistically significant difference（ P < 0. 05）. After treatment

the serum levels of TNF-α

IL-1β and IL-6 in the combination treatment group were significantly lower than those in the r TMS group; the levels of GSH-Px in the combination treatment group were significantly higher than those in the r TMS group

while the levels of LPO and MDA in the combination treatment group were significantly lower than those in the r TMS treatment group

with statistically significant difference（ P<0. 05）. Compared with the r TMS treatment group after treatment

HAMA score and HAMD score of the combination treatment group decreased significantly

and the differences were statistically significant（ P<0. 05）. The total effective rate of the combination treatment group was 89. 66%（ 52/58）

significantly higher than75. 86%（ 44/58） of the r TMS treatment group

the difference was statistically significant（ P < 0. 05）.CONCLUSIONS: The efficacy of nimodipine combined with r TMS in the treatment of patients with subcortical nondementia vascular cognitive impairment is significant

which can improve the cognitive function and daily life ability of patients

regulate the level of serum S100β

NSE and IGF-1

reduce the inflammatory response of brain tissues

improve the antioxidant capacity and the depression and anxiety of patients.